A comprehensive map of genes necessary for cancer survival is one step closer, following the validation of the two largest CRISPR-Cas9 genetic screens in 725 cancer models, across 25 different cancer types.

Scientists at the Wellcome Sanger Institute and the Broad Institute of MIT and Harvard compared the consistency of the two datasets, independently verifying the methodology and findings.

The results, published in Nature Communications, mean that the two datasets can be integrated to form the largest genetic screen of cancer cell lines to date, which will provide the basis for the Cancer Dependency Map in around 1,000 cancer models.

The scale of this combined dataset will help to speed up the discovery and development of new cancer drugs.

The Cancer Dependency Map (Cancer DepMap) initiative aims to create a detailed rulebook of precision cancer treatments for patients.

Two key elements of the Cancer DepMap are the mapping of the genes critical for the survival of cancer cells and analytics of the resulting datasets.

Despite recent advances in cancer research, making precision medicine widely available to cancer patients requires many new drug targets.

To find these drug targets, Cancer DepMap researchers take tumour cells from patients to create cell lines that can be grown in the laboratory.

They then use CRISPR-Cas9 technology to edit the genes in these cancer cells, turning them off one-by-one to measure how critical they are for the cancer to survive.

The results of these experiments indicate which genes are the most likely to make viable drug targets.

In this new study, researchers analysed data from two recently published CRISPR-Cas9 genetic screens performed on cancer cell lines at the Broad and Sanger Institutes.

Despite significant differences in experimental protocols, the team found that the screen results were consistent with one another.

Crucially, the same genes essential to cancer survival - known as dependencies - were found in both datasets.

Dr Clare Pacini, a first author of the study from the Wellcome Sanger Institute and Open Targets, said: "The Sanger and Broad Institute CRISPR-Cas9 screens were created using slightly different protocols, such as cell growth duration and reagents used. To verify each Institute's dataset, we have repeated CRISPR-Cas9 screens using the protocols originally employed at the other Institute. Importantly, we have found the same genetic dependencies in each, meaning the new drug targets originally identified are consistent."

Aviad Tsherniak, of the Broad Institute of MIT and Harvard, said: "This is the first analysis of its kind and is really important for the whole cancer research community. Not only have we reproduced common and specific dependencies across the two datasets, but we have taken biomarkers of gene dependency found in one dataset and recovered them in the other. Our analysis has been unbiased, rigorous and proves the veracity of the approach and the drug targets identified."

In 2013, results comparing two large pharmacogenomic datasets employing the cancer models used in this study raised concerns about the reproducibility of the experiments performed.

Further independently-published analyses eventually proved the two resources to be reliable and consistent, restoring confidence in the robustness of large-scale drug screens, but the episode slowed the progress of cancer research.

This study validates the reproducibility of CRISPR-Cas9 functional genetic screens in order to remove any doubt about their efficacy.

It sets rigorous standards for assessing these new types of dataset, facilitating the comparison and integration of large databases of cancer dependencies.

Dr Francesco Iorio, of the Wellcome Sanger Institute and Open Targets, said: "It is worth remembering that when these datasets were originally produced we were dealing with a new, unproven technology. This study is important because it demonstrates the validity of the experimental methods and the consistency of the data that they produce. It also means that two large cancer dependency datasets are compatible. By joining them together, we will have access to much greater statistical power to narrow down the list of targets for the next generation of cancer treatments."

Source: Wellcome Sanger Institute